NZ501345A - Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent - Google Patents

Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent

Info

Publication number
NZ501345A
NZ501345A NZ501345A NZ50134598A NZ501345A NZ 501345 A NZ501345 A NZ 501345A NZ 501345 A NZ501345 A NZ 501345A NZ 50134598 A NZ50134598 A NZ 50134598A NZ 501345 A NZ501345 A NZ 501345A
Authority
NZ
New Zealand
Prior art keywords
compound
use according
glucosidase inhibitor
tablet
medicament comprises
Prior art date
Application number
NZ501345A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ501345A publication Critical patent/NZ501345A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
NZ501345A 1997-06-18 1998-07-15 Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent NZ501345A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (fr) 1997-06-18 1998-06-15 Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases

Publications (1)

Publication Number Publication Date
NZ501345A true NZ501345A (en) 2001-10-26

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ501345A NZ501345A (en) 1997-06-18 1998-07-15 Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent

Country Status (24)

Country Link
EP (1) EP0975343A1 (fr)
JP (1) JP2001523271A (fr)
KR (1) KR20010013845A (fr)
CN (1) CN1274282A (fr)
AP (1) AP9901720A0 (fr)
AR (2) AR013352A1 (fr)
AU (1) AU8799998A (fr)
BG (1) BG103966A (fr)
BR (1) BR9810186A (fr)
CA (1) CA2294134A1 (fr)
CO (1) CO4940453A1 (fr)
DZ (1) DZ2519A1 (fr)
EA (1) EA200000040A1 (fr)
IL (1) IL133138A0 (fr)
MA (1) MA26510A1 (fr)
NO (1) NO996270D0 (fr)
NZ (1) NZ501345A (fr)
OA (1) OA11631A (fr)
PE (1) PE89199A1 (fr)
PL (1) PL337577A1 (fr)
SK (1) SK179499A3 (fr)
TR (1) TR199903072T2 (fr)
UY (1) UY25051A1 (fr)
WO (1) WO1998057635A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351686A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Novel pharmaceutical
WO2002080936A1 (fr) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
UY25051A1 (es) 2000-09-29
NO996270L (no) 1999-12-17
DZ2519A1 (fr) 2003-02-01
AR014881A1 (es) 2001-04-11
TR199903072T2 (xx) 2000-07-21
OA11631A (en) 2004-11-22
KR20010013845A (ko) 2001-02-26
CO4940453A1 (es) 2000-07-24
AR013352A1 (es) 2000-12-27
NO996270D0 (no) 1999-12-17
BG103966A (bg) 2000-07-31
BR9810186A (pt) 2000-08-08
MA26510A1 (fr) 2004-12-20
SK179499A3 (en) 2000-11-07
EA200000040A1 (ru) 2000-08-28
CA2294134A1 (fr) 1998-12-23
EP0975343A1 (fr) 2000-02-02
IL133138A0 (en) 2001-03-19
WO1998057635A1 (fr) 1998-12-23
JP2001523271A (ja) 2001-11-20
PE89199A1 (es) 1999-10-23
CN1274282A (zh) 2000-11-22
PL337577A1 (en) 2000-08-28
AP9901720A0 (en) 1999-12-31
AU8799998A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
AP1279A (en) Treatment of diabetes with thiazolidinedione and metformin.
US20030109553A1 (en) Treatment of diabetes with thiazolidinedione and metformin
EP1001783A1 (fr) Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et du biguanide
WO1998057636A1 (fr) Nouvelle methode de traitement
NZ501345A (en) Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent
WO1999003478A1 (fr) Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase
NZ501163A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide
US20020123514A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
NZ515554A (en) Treatment of diabetes with thiazolidinedione and metformin
AU1011902A (en) Treatment of diabetes with thiazolidinedione and metformin
CA2549864A1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de metformine
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
AU1540002A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA99012078A (en) Treatment of diabetes with thiazolidinedione and metformin
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU2928002A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide

Legal Events

Date Code Title Description
PSEA Patent sealed